Basic Information

Academic Degree

• 博士（医学）(東京大学)

ID,URL

• ORCID ID

  0000-0001-8401-6074

• J-Global ID

  202001006112916282

• Researcher number

  40579710

researchmap URL

• https://researchmap.jp/sunagai

Research

Papers

• Regulatory Approval of CAR-T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan.

  Kensuke Matsuda; Atsushi Nonami; Kayo Shinohara; Sumimasa Nagai

  Clinical pharmacology and therapeutics, 14 Mar. 2025, Peer-reviewed, Last author

  
• Characteristics of Drugs from Non-Global Companies for Hematologic Malignancies and Impact on Global Regulatory Approval.

  Kensuke Matsuda; Sumimasa Nagai; Koichi Sugimoto

  Clinical pharmacology and therapeutics, Jan. 2025, Peer-reviewed

  
• Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.

  Kensuke Matsuda; Sumimasa Nagai; Koichi Sugimoto

  Japanese journal of clinical oncology, 07 Dec. 2023, Peer-reviewed

  
• Recommendations related to the analytical equivalence assessment of gene panel testing.

  Sumimasa Nagai; Hiroshi Nishihara; Takayoshi Suzuki; Kazuto Nishio; Hiroya Taniguchi; Katsuya Tsuchihara; Kohei Nakamura; Reika Takamatsu; Toshihide Ueno; Hiroyuki Aburatani; Takashi Kohno; Shinji Kohsaka

  Cancer science, Oct. 2022, Peer-reviewed, Lead author, Corresponding author

  Access this paper :

  
• Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions.

  Sumimasa Nagai; Bartlett Witherspoon; Chadi Nabhan; Charles L Bennett

  Cancer treatment and research, 2022

  
• Tumor mutational burden measurement using comprehensive genomic profiling assay.

  Hidenori Kage; Shinji Kohsaka; Kenji Tatsuno; Toshihide Ueno; Masachika Ikegami; Koichi Zokumasu; Aya Shinozaki-Ushiku; Sumimasa Nagai; Hiroyuki Aburatani; Hiroyuki Mano; Katsutoshi Oda

  Japanese journal of clinical oncology, 05 Aug. 2022, Peer-reviewed

  
• Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

  Gita Thanarajasingam; Lori M Minasian; Vishal Bhatnagar; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; Nicole Gormley; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Yok Lam Kwong; Richard F Little; Matthew J Matasar; Maria-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Abhilasha Nair; Loretta Nastoupil; Kaye Robertson; Surbhi Sidana; Karin E Smedby; Pieter Sonneveld; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; John F Seymour; Thomas M Habermann

  The Lancet. Haematology, May 2022, Peer-reviewed

  
• Regulatory hurdles for CAR T-cell therapy in Japan

  Sumimasa Nagai

  The Lancet Haematology, Oct. 2021, Invited, Lead author, Last author, Corresponding author

  
• Current situation of oncology biosimilars in Japan.

  Sumimasa Nagai

  The Lancet Oncology, Mar. 2021, Lead author, Last author, Corresponding author

  
• The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.

  Charles L Bennett; Sumimasa Nagai; Andrew C Bennett; Shamia Hoque; Chadi Nabhan; Martin W Schoen; William J Hrushesky; Stefano Luminari; Paul Ray; Paul R Yarnold; Bart Witherspoon; Josh Riente; Laura Bobolts; John Brusk; Rebecca Tombleson; Kevin Knopf; Marc Fishman; Y Tony Yang; Kenneth R Carson; Benjamin Djulbegovic; John Restaino; James O Armitage; Oliver A Sartor

  The oncologist, 14 Feb. 2021, Peer-reviewed

  
• Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.

  Sumimasa Nagai

  International journal of molecular sciences, 03 Aug. 2019, Peer-reviewed, Invited, Lead author, Last author, Corresponding author

  
• Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.

  Roberto Salgado; David B Solit; David L Rimm; Jan Bogaerts; Renzo Canetta; Tracy Lively; Kim Lyerly; Paul N Span; Alison Bateman-House; Amr Makady; L Bergmann; Sumimasa Nagai; Chris Smith; Mark Robson; Mary Savage; Emile Voest; Christopher Sweeney; Philippe Lambin; Marlene Thomas; Lyndsay Harris; Denis Lacombe; Chistophe Massard

  European journal of cancer (Oxford, England : 1990), Jun. 2019, Peer-reviewed

  
• Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

  Brian Chen; Sumimasa Nagai; James O Armitage; Bartlett Witherspoon; Chadi Nabhan; Ashley C Godwin; Y Tony Yang; Anuhya Kommalapati; Sri Harsha Tella; Carlo DeAngelis; Dennis W Raisch; Oliver Sartor; William J Hrushesky; Paul S Ray; Paul R Yarnold; Bryan L Love; LeAnn B Norris; Kevin Knopf; Laura Bobolts; Joshua Riente; Stefano Luminari; Robert C Kane; Shamia Hoque; Charles L Bennett

  The oncologist, Apr. 2019, Peer-reviewed, Lead author

  
• Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?

  Zaina P Qureshi; Sumimasa Nagai; Charles L Bennett

  JAMA oncology, 01 Mar. 2019

  
• Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan.

  Sumimasa Nagai; Daisuke Sugiyama

  Clinical therapeutics, Jan. 2019, Peer-reviewed, Invited, Lead author, Corresponding author

  
• Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers.

  H Kim Lyerly; Jun Ren; Renzo Canetta; Gi Hyun Kim; Sumimasa Nagai; Tomohiro Yamaguchi; Ken Hatogai; Hiroshi Katayama; Silvy Da Rocha Dias; Daniel McManus; Kathy Soltys; Zhimin Yang; Olufumilayo Olopade; Nancy Goodman; Greg Reaman; Thomas Gross

  Journal of global oncology, Dec. 2018, Peer-reviewed

  
• Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann

  The Lancet Haematology, Nov. 2018, Peer-reviewed

  
• Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.

  Sumimasa Nagai; Keiya Ozawa

  Investigational new drugs, Jun. 2018, Peer-reviewed, Lead author, Corresponding author

  
• Societal challenges of precision medicine: Bringing order to chaos

  Roberto Salgado; on behalf of; Helen Moore; John W.M. Martens; Tracy Lively; Shakun Malik; Ultan McDermott; Stefan Michiels; Jeffrey A. Moscow; Sabine Tejpar; Tawnya McKee; Denis Lacombe; Robert Becker; Philip Beer; Jonas Bergh; Jan Bogaerts; Simon Dovedi; Antonio T. Fojo; Moritz Gerstung; Vassilis Golfinopoulos; Stephen Hewitt; Daniel Hochhauser; Hartmut Juhl; Robert Kinders; Thomas Lillie; Kim Lyerly Herbert; Shyamala Maheswaran; Mehdi Mesri; Sumimasa Nagai; Irene Norstedt; Daniel O'Connor; Kathy Oliver; Wim J.G. Oyen; Francesco Pignatti; Eric Polley; Nitzan Rosenfeld; Jan Schellens; Richard Schilsky; Erasmus Schneider; Adrian Senderowicz; Olli Tenhunen; Augustinus van Dongen; Christine Vietz; Nils Wilking

  European Journal of Cancer, 01 Oct. 2017, Peer-reviewed

  
• Generic drugs in oncology - Authors' reply.

  Charles L Bennett; Sumimasa Nagai; Y Tony Yang; Brian K Chen; Oliver Sartor; James O Armitage

  The Lancet Oncology, Feb. 2017

  
• New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.

  Sumimasa Nagai; Keiya Ozawa

  Current gene therapy, 2017, Peer-reviewed, Invited, Lead author, Corresponding author

  
• Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.

  Sumimasa Nagai; Keiya Ozawa

  Investigational new drugs, Dec. 2016, Peer-reviewed, Lead author, Corresponding author

  
• Generic oncology drugs: are they all safe?

  Y Tony Yang; Sumimasa Nagai; Brian K Chen; Zaina P Qureshi; Akida A Lebby; Samuel Kessler; Peter Georgantopoulos; Dennis W Raisch; Oliver Sartor; Terhi Hermanson; Robert C Kane; William J Hrushesky; Joshua J Riente; LeAnn B Norris; Laura R Bobolts; James O Armitage; Charles L Bennett

  The Lancet Oncology, Nov. 2016, Peer-reviewed, Lead author

  
• Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.

  Sumimasa Nagai; Keiya Ozawa

  British journal of haematology, Jul. 2016, Peer-reviewed, Lead author, Corresponding author

  
• Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.

  Sumimasa Nagai; Keiya Ozawa

  International journal of hematology, Jul. 2016, Peer-reviewed, Lead author, Corresponding author

  
• Evolving Japanese regulations on companion diagnostics.

  Sumimasa Nagai; Masaaki Urata; Hiroyuki Sato; Motoki Mikami; Wataru Kuga; Reiko Yanagihara; Daisei Miyamoto; Yuka Suzuki; Mayumi Shikano

  Nature biotechnology, Feb. 2016, Peer-reviewed, Lead author, Corresponding author

  
• Japanese regulatory authority's perspective on biosimilars.

  Sumimasa Nagai; Reiko Yanagihara; Yasuhiro Kishioka

  The Lancet Oncology, Mar. 2015, Lead author, Corresponding author

  
• [Exploratory biomarker analyses and companion diagnostics].

  Sumimasa Nagai

  Nihon rinsho. Japanese journal of clinical medicine, Feb. 2015, Invited, Lead author, Last author, Corresponding author

  
• The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.

  Sumimasa Nagai; Tsuyoshi Takahashi; Mineo Kurokawa

  Current stem cell research & therapy, Dec. 2010, Peer-reviewed, Invited, Lead author

  
• Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia.

  Sumimasa Nagai; Yasuhito Nannya; Tsuyoshi Takahashi; Mineo Kurokawa

  Annals of hematology, Jul. 2010, Peer-reviewed, Lead author

  
• How should we prevent hematologic relapse of acute promyelocytic leukemia?

  Sumimasa Nagai; Tsuyoshi Takahashi; Mineo Kurokawa

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 Feb. 2010, Lead author

  
• Risk-adapted maintenance therapy for acute promyelocytic leukemia.

  Sumimasa Nagai; Tsuyoshi Takahashi; Mineo Kurokawa

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 Jan. 2010, Lead author

  
• Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.

  Koki Ueda; Sumimasa Nagai; Shin-ich Miyashita; Toshikazu Kaise; Motoshi Ichikawa; Keiki Kumano; Akira Hangaishi; Yasuhito Nannya; Mineo Kurokawa

  Leukemia research, Jan. 2010, Peer-reviewed

  
• Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia.

  Sumimasa Nagai; Yasuhito Nannya; Shunya Arai; Yumiko Yoshiki; Tsuyoshi Takahashi; Mineo Kurokawa

  Haematologica, Jan. 2010, Peer-reviewed, Lead author

  
• Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.

  Sumimasa Nagai; Tsuyoshi Takahashi; Mineo Kurokawa

  CNS & neurological disorders drug targets, Nov. 2009, Peer-reviewed, Invited, Lead author

  
• The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia.

  Sumimasa Nagai; Yasuhito Nannya; Akira Hangaishi; Tsuyoshi Takahashi; Mineo Kurokawa

  Leukemia research, Oct. 2009, Peer-reviewed, Lead author

  
• Simultaneous appearance of methotrexate-associated lymphoproliferative disorder and tuberculous meningitis demonstrating the definitive role of immunosuppression.

  Sumimasa Nagai; Koji Izutsu; Takuro Watanabe; Mineo Kurokawa

  Annals of hematology, Jun. 2009, Peer-reviewed, Lead author

  
• Maintenance and preemptive therapy with ganciclovir for cytomegalovirus colitis with extremely high antigenemia in adult T-cell leukemia.

  Sumimasa Nagai; Masaki Toshima; Kazuya Sato; Masaki Mori; Tadashi Nagai; Kazuo Muroi; Keiya Ozawa

  International journal of hematology, Mar. 2009, Peer-reviewed, Lead author

  
• Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia.

  Sumimasa Nagai; Takashi Asai; Takuro Watanabe; Kumi Oshima; Akira Hangaishi; Yoshinobu Kanda; Toru Motokura; Shigeru Chiba; Shigeki Aoki; Kuni Ohtomo; Mineo Kurokawa

  Annals of hematology, Jul. 2008, Peer-reviewed, Lead author

  
• Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR alpha fusion gene.

  Keisuke Kataoka; Koji Izutsu; Sumimasa Nagai; Akira Hangaishi; Toru Motokura; Tsuyoshi Takahashi; Mineo Kurokawa

  International journal of hematology, May 2008, Peer-reviewed

  
• The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.

  Sumimasa Nagai; Motoshi Ichikawa; Tsuyoshi Takahashi; Hiroyuki Sato; Hiromitsu Yokota; Kumi Oshima; Koji Izutsu; Akira Hangaishi; Yoshinobu Kanda; Toru Motokura; Shigeru Chiba; Yutaka Yatomi; Mineo Kurokawa

  Experimental hematology, Nov. 2007, Peer-reviewed, Lead author

  
• Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients.

  Kumi Oshima; Yoshinobu Kanda; Yuki Asano-Mori; Nahoko Nishimoto; Shunya Arai; Sumimasa Nagai; Hiroyuki Sato; Takuro Watanabe; Noriko Hosoya; Koji Izutsu; Takashi Asai; Akira Hangaishi; Toru Motokura; Shigeru Chiba; Mineo Kurokawa

  The Journal of antimicrobial chemotherapy, Aug. 2007, Peer-reviewed

  

Misc.

• 総論 アカデミア発の医療開発の現状と課題

  永井 純正

  BIO Clinica, Dec. 2023

  
• 医薬品の開発と承認制度の国際比較

  永井純正

  公衆衛生, Feb. 2023

  
• 第32回抗悪性腫瘍薬開発フォーラム「抗悪性腫瘍薬の開発における臨床研究中核病院・橋渡し拠点の貢献」総合討論

  永井純正; 熊谷明子; 大矢俊雄

  腫瘍内科, Nov. 2022

  
• 医師主導治験の現状と課題

  永井 純正

  腫瘍内科, Apr. 2022

  
• がんゲノムプロファイリング検査

  永井純正

  がんゲノム病理学, Nov. 2021

  
• 新医薬品等の承認審査制度、行政

  永井 純正

  CRCテキストブック第４版, Mar. 2021

  
• がん治療のレギュラトリーサイエンス

  永井 純正

  腫瘍内科, Dec. 2020

  
• 遺伝子パネル検査によって変わる今後の医療と医薬品開発 国内承認品目の審査報告書を読み解いて学ぶこと

  永井 純正

  Pharm Stage, Sep. 2020

  
• 血液悪性腫瘍に対する治療薬薬事承認の現状

  永井 純正

  臨床血液, May 2020, Peer-reviewed

  
• 新薬承認における日米の違い

  永井 純正

  内科 = Internal medicine : 臨床雑誌, Mar. 2018

  
• International comparison of regulations on oncologic drugs and companion diagnostics

  永井 純正

  血液内科 = Hematology, Jul. 2017

  
• ゲノム編集によるAIDS・血液疾患の治療 (今月の臨床 万能幹細胞・幹細胞とゲノム編集 : 再生医療の進歩が医療を変える) -- (ES細胞・iPS細胞の臨床応用)

  永井 純正

  臨床婦人科産科, May 2017

  
• Regulations on companion diagnostics

  永井 純正

  腫瘍内科 = Clinical oncology, Apr. 2017

  
• Marketing authorization of companion diagnostics using next generation sequencing or liquid biopsies

  永井 純正

  腫瘍内科 = Clinical oncology, Nov. 2016

  
• 医薬品の開発および評価における留意点 (特集 個別化医療とコンパニオン診断薬を取り巻く現状と問題点)

  永井 純正

  医薬ジャーナル, Aug. 2015

  
• Points to consider in development and evaluation of oncologic drugs with companion diagnostics

  永井 純正

  腫瘍内科 = Clinical oncology, May 2015

  
• 産業と行政 日本および欧米におけるコンパニオン診断薬の規制の現状および今後の展望

  永井 純正

  バイオサイエンスとインダストリー, 2015

  
• The present situation of development and regulatory review of marketing authorization of companion diagnostics in oncology

  永井 純正

  Pharm stage, Nov. 2014

  
• The role of regulatory agencies in the development of new drugs for hematologic malignancy

  永井 純正

  血液内科, Jul. 2014

  
• The progress of the therapeutic target analysis in acute promyelocytic leukemia

  永井 純正

  血液内科, Apr. 2011

  
• Monitoring of minimal residual disease in acute promyelocytic leukemia

  永井 純正

  血液・腫瘍科, Mar. 2010

  
• Degradation of PML-RARα induced by arsenic trioxide

  永井 純正

  血液・腫瘍科, Jan. 2009

  

External funds: Kakenhi

• Study on a conditional approval system that contributes to early access to anticancer drugs

  Grant-in-Aid for Scientific Research (C)

  Basic Section 47060:Clinical pharmacy-related

  Kyoto University;The University of Tokyo

  Sumimasa Nagai

  From 01 Apr. 2018, To 31 Mar. 2024, Project Closed

  抗癌剤;薬事規制;薬事承認

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K06779/
• Clinical data for conditional approval of regenerative medical products for cancer

  Grant-in-Aid for Young Scientists (B)

  The University of Tokyo

  Sumimasa NAGAI

  From 01 Apr. 2015, To 31 Mar. 2018, Project Closed

  抗癌剤;薬事承認;再生医療等製品;薬事規制;抗がん剤

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K20967/
• 急性骨髄性白血病予後不良因子BAALCの機能解析

  Grant-in-Aid for Research Activity Start-up

  The University of Tokyo

  永井 純正

  From 01 Apr. 2011, To 31 Mar. 2012, Project Closed

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23890042/
• 癌領域の医薬品、診断薬、再生医療の開発早期に必要な臨床データに関する研究

  Grant-in-Aid for Scientific Research (C)

  Basic Section 90140:Medical technology assessment-related

  Kyoto University

  永井 純正

  From 01 Apr. 2022, To 31 Mar. 2026, Granted

  抗癌剤;薬事規制;条件付き承認

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K12884/

Education

Teaching subject(s)

• From 01 Apr. 2025, To 31 Mar. 2026

  Translational & Clinical Research Management

  E068, Year-long, Graduate School of Medicine, 2
• From 01 Apr. 2024, To 31 Mar. 2025

  Translational & Clinical Research Management

  E068, Year-long, Graduate School of Medicine, 2
• From 01 Apr. 2023, To 31 Mar. 2024

  Translational & Clinical Research Management

  E068, Year-long, Graduate School of Medicine, 2
• From 01 Apr. 2022, To 31 Mar. 2023

  Translational & Clinical Research Management

  E068, Year-long, Graduate School of Medicine, 2

Participation in PhD Defense

• Genetic analysis of myeloid neoplasms with der(1;7)(q10;p10)

  OKUDA RURIKA, Graduate School of Medicine, Chief Examiner

  24 Mar. 2025
• The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data

  ITOSHIMA HISASHI, Graduate School of Medicine, Sub-chief Examiner

  24 Mar. 2025
• Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

  Tomoki Iemura, Graduate School of Medicine, Sub-chief Examiner

  24 Mar. 2025
• Newly developed preclinical models reveal broad spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide

  MATSUOKA TAKASHI, Graduate School of Medicine, Sub-chief Examiner

  25 Mar. 2024
• Modified gelatin hydrogel nonwoven fabrics (Genocel) as a skin substitute in murine skin defects

  LI YUANJIAOZI, Graduate School of Medicine, Chief Examiner

  25 Mar. 2024
• Oncologic benefit of adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and curative surgery with selective lateral pelvic lymph node dissection: An international retrospective cohort study

  FUKUI YUDAI, Graduate School of Medicine, Sub-chief Examiner

  24 Jul. 2023
• RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia

  KUBOTA HIROHITO, Graduate School of Medicine, Sub-chief Examiner

  25 Mar. 2024
• Predicting the efficacy of monoclonal antibodies against multiple myeloma

  SHIMAZU YUTAKA, Graduate School of Medicine, Sub-chief Examiner

  25 Mar. 2024
• Associations of pulmonary and extrapulmonary computed tomographic manifestations with impaired physical activity in symptomatic patients with chronic obstructive pulmonary disease

  HAMAKAWA YOKO, Graduate School of Medicine, Sub-chief Examiner

  23 May 2023
• Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis

  SAIKI RYUNOSUKE, Graduate School of Medicine, Sub-chief Examiner

  23 Mar. 2023
• Clinically relevant model of oxaliplatin-induced sinusoidal obstruction syndrome

  TODA REI, Graduate School of Medicine, Sub-chief Examiner

  23 Mar. 2023
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

  AJIMIZU HITOMI, Graduate School of Medicine, Sub-chief Examiner

  26 Sep. 2022
• HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function

  MITANI YOSUKE, Graduate School of Medicine, Sub-chief Examiner

  26 Sep. 2022

Administration

School management (title, position)

• From 01 Apr. 2024, To 31 Mar. 2025

  病院協議会

Faculty management (title, position)

• From 01 Oct. 2022, To 30 Sep. 2024

  管理体制委員会委員
• From 01 Apr. 2022, To 31 Mar. 2023

  病院協議会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構協議会
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構執行部会議　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構財務委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構人事委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構推進委員会
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構ACTION-K推進委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構支援研究検討・管理会議　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  先端医療研究開発機構　次世代医療・iPS細胞治療研究センター運営委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  先進医療・患者申出療養専門委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  特定臨床研究等実施管理委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  研究開発戦略推進委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  シーズ発掘委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  シーズ選定評価委員会　委員
• From 01 Apr. 2022, To 31 Mar. 2023

  非臨床開発・薬事連絡会　委員長
• From 01 Apr. 2022, To 31 Mar. 2023

  知財・技術移転連絡会　委員長